REG - Venture Life Group - Directorate Changes

Venture LifeAnnouncement

30/05/2022 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220530:nRSd1614Na&default-theme=true

RNS Number : 1614N  Venture Life Group PLC  30 May 2022

30(th) May 2022

 

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Directorate Changes

 

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the self-care market, announces that Mr Peter
Bream, non-executive Director and Chair of the Audit Committee, after serving
on the Board for seven years, has given the Company notice of his resignation
in order to facilitate Director rotation in line with good corporate
governance.

The Company also announces that Mr Carl Dempsey, non-executive Director and
Chair of the Remuneration Committee will also be stepping down. Mr Dempsey has
served on the Board of the Company for three years, but has decided that, due
to the workload required from his other business interests, and accelerating
new ventures, he is unable to continue to dedicate the required time to his
position on the Board of Venture Life.

A search process has begun to replace both Mr Bream and Mr Dempsey, and they
will both continue to serve on the Board of the Company until their
replacements are appointed.

 

Jerry Randall, CEO of Venture Life commented: "I would like to extend my
thanks to both Peter and Carl on behalf of myself and the whole team of
Venture Life for all of their advice, support and input to the business over
the time they have been with us. The business has grown significantly over
their time with us, and in the last few years managed its way through
significant challenges that the global markets have experienced. I wish both
Peter and Carl the very best for their future endeavours."

Paul McGreevy, non-executive Chair of Venture Life commented: "It's clearly
evident that both Peter and Carl's contribution to the business has been
significant in our governance, compliance and growth, and have helped build a
sustainable platform from which we can accelerate our ambitions. I'd like to
thank them both for their professionalism and support given to Venture Life."

 

 

For further information, please contact:

 

 Venture Life Group PLC                              +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cenkos Securities plc (Nomad and Joint Broker)      +44 (0) 20 7397 8900
 Michael Johnson/Russell Kerr (Sales)

 Stephen Keys/Camilla Hume (Corporate Finance)

 Singer Capital markets (Joint Broker)               +44 (0) 20 7496 3000
 Jonathan Dighe (Sales)

 Shaun Dobson/Alaina Wong (Corporate Finance)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The Netherlands and
Sweden, the Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Active range in the
area of women's intimate healthcare, the Lift and Glucogel product ranges for
hypoglycaemia, products for fungal infections and proctology, and
dermo-cosmetics for addressing the signs of ageing. Its products are sold in
over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFZGZKRLRGZZM